...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacogenomics >The effect of rs5758550 on CYP2D6(star)2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen
【24h】

The effect of rs5758550 on CYP2D6(star)2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen

机译：使用Tamoxifen对乳腺癌患者CYP2D6（星）2表型和肠毒素形成的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: CYP2D6(star)2 is considered fully active, but it has been suggested that it only happens in the presence of rs5758550. This study aims to elucidate the impact of this enhancer. Materials & methods: DNA and blood samples from women enrolled in the CYPTAM study (NTR1509) were analyzed. Fourteen CYP2D6(star)2 carriers without the enhancer were reclassified. The relationship of CYP2D6 phenotypes and drug levels was studied. Results: After correction for the absence of the enhancer, the correlation between CYP2D6 phenotypes and endoxifen did not improve (R-2: 0.290 vs 0.279). No difference was observed in mean concentrations between CYP2D6(star)2 individuals with and without the enhancer. Conclusion: The rs5758550 enhancer does not lead to improved prediction of endoxifen levels in breast cancer patients.
机译：目的：CYP2D6（星）2被认为是完全活跃的，但有人建议它只发生在RS5758550的存在。 本研究旨在阐明这种增强剂的影响。 分析了材料和方法：分析了患有Cyptam研究（NTR1509）的妇女的DNA和血液样本。 14个CYP2D6（星）2载体没有增强剂的载体被重新分类。 研究了CYP2D6表型和药物水平的关系。 结果：校正缺乏增强剂后，CYP2D6表型和内胃癌之间的相关性未改善（R-2：0.290 Vs 0.279）。 在CYP2D6（星）2个体之间的平均浓度下没有差异，没有增强剂。 结论：RS5758550增强剂不会导致乳腺癌患者内胃癌水平的预测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号